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Background: There is currently no consensus on the duration of hospitalization required after TAVI. We report the feasibility and safety of 
early discharge after transfemoral transcatheter aortic valve implantation (TAVI) with the Edwards SAPIEN-XT prosthesis.
methods: Between 2009 and 2013, 337 patients underwent transfemoral TAVI with the Edwards SAPIEN-XT prosthesis using local 
anesthesia and were discharged home either early (< 3 days, Early Discharge group, n=121) or after 3 days (Conventional Discharge 
group, n=216). The primary end-point of the study combined death and re-hospitalization from discharge to 30-day follow-up.
results: Patients in the Early Discharge group were less symptomatic (NYHA>III: 64.5% vs. 75.5%, p=0.01) and had less renal 
failure (Creatinine: 102.1±41.0 vs. 113.3±58.9 µmol/l, p=0.04), atrial fibrillation (33.1% vs. 46.3%, p=0.02), and previous balloon aortic 
valvuloplasty (11.6% vs. 23.1%, p=0.01) and were more likely to have a pacemaker before TAVI (16.5% vs. 8.3%, p=0.02). Pre-existing 
pacemaker (OR 2.27; 95% CI 1.01-5.26) and the absence of elevated creatinine (OR 1.01; 95% CI 1.01-1.02) were independent positive 
predictors of an early discharge, whereas previous balloon aortic valvuloplasty (OR 0.44; 95% CI 0.22-0.91), and post-TAVI blood 
transfusions (OR 0.10; 95% CI 0.03-0.42), were independent negative predictors of early discharge. The primary end-point occurred in 4 
(3.3%) patients in the Early Discharge group and in 11 (5.1%) patients in the Conventional Discharge group (p=0.58).
conclusion:  The results of our study suggest that early discharge after transfemoral TAVI using the Edwards-SAPIEN XT prosthesis is 
feasible and safe in selected patients.
